There are currently 486 clinical trials in Little Rock, Arkansas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Arkansas for Medical Sciences, Arkansas Children's Hospital, GSK Investigational Site and Arkansas Cancer Research Center at University of Arkansas for Medical Sciences. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
NCT05803421
Recruiting
The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: KLR Business Group, Inc. dba Arkansas Clinical Research, Little Rock, Arkansas
Conditions: Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
Register for Updates
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
NCT05595642
Recruiting
This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
06/17/2024
Locations: Lynn Institute of The Ozarks - ERN - PPDS, Little Rock, Arkansas
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Register for Updates
Vamikibart in Participants With Uveitic Macular Edema
NCT05642325
Recruiting
This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: University of Arkansas For Medical Sciences, Little Rock, Arkansas
Conditions: Uveitic Macular Edema
Register for Updates
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
NCT05884398
Recruiting
The purpose of the study is to determine if the intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensitive prostate cancer (mCSPC) who reached a prostate-specific antigen (PSA) level < 0.2 nanograms/millilitres (ng/mL) after 6 months of treatment with apalutamide and ADT combination therapy provides non-inferior radiographic progression-free survival (rPFS) and a reduced burden of hot flashes measured as 18-month percent change in severity adjusted... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Arkansas Urology, Little Rock, Arkansas
Conditions: Metastatic Castrate-sensitive Prostate Cancer
Register for Updates
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
NCT04396236
Recruiting
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/17/2024
Locations: Arkansas Children's, Little Rock, Arkansas
Conditions: Migraine
Register for Updates
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
NCT04396574
Recruiting
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/17/2024
Locations: Arkansas Children's, Little Rock, Arkansas
Conditions: Migraine
Register for Updates
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
NCT06074562
Recruiting
The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately 24 weeks, across 3 study periods.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Preferred Research Partners, Little Rock, Arkansas
Conditions: Diabetic Peripheral Neuropathy
Register for Updates
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
NCT05675449
Recruiting
The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept. There are 2 parts to this study. Part 1 will evaluate the safety and tolerability of elranatamab when given in combination with carfilzomib plus dexamethasone. Part 2 has 2 arms. The first will evaluate the safety and tolerability of elranatamab when given in combination with maplirpacept. The second will identify the optim... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Multiple Myeloma
Register for Updates
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
NCT05929066
Recruiting
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Medical Investigations, Little Rock, Arkansas
Conditions: Obesity, Overweight, Knee Pain Chronic, Knee Osteoarthritis, Obstructive Sleep Apnea
Register for Updates
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
NCT05929079
Recruiting
The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Preferred Research Partners, Little Rock, Arkansas
Conditions: Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
Register for Updates
A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma
NCT04576117
Recruiting
This phase III trial investigates the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine to selumetinib compared to selumetinib alone in treating children and young adults with low-grade glioma (a common type of brain cancer) that has come back after prior treatment (recurrent) or does not respond to therapy (progressive). Selumetinib is a drug that works by blocking a protein that lets tumor cells grow without stopping. Vinblastine blocks cell growth... Read More
Gender:
All
Ages:
Between 2 years and 25 years
Trial Updated:
06/15/2024
Locations: Arkansas Children's Hospital, Little Rock, Arkansas
Conditions: Recurrent Low Grade Astrocytoma, Refractory Low Grade Astrocytoma, Refractory Low Grade Glioma, Recurrent WHO Grade 2 Glioma, Refractory WHO Grade 1 Glioma
Register for Updates
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
NCT03871257
Recruiting
This phase III trial studies if selumetinib works just as well as the standard treatment with carboplatin/vincristine (CV) for subjects with NF1-associated low grade glioma (LGG), and to see if selumetinib is better than CV in improving vision in subjects with LGG of the optic pathway (vision nerves). Selumetinib is a drug that works by blocking some enzymes that low-grade glioma tumor cells need for their growth. This results in killing tumor cells. Drugs used as chemotherapy, such as carboplat... Read More
Gender:
All
Ages:
Between 2 years and 21 years
Trial Updated:
06/15/2024
Locations: Arkansas Children's Hospital, Little Rock, Arkansas
Conditions: Low Grade Glioma, Neurofibromatosis Type 1, Visual Pathway Glioma
Register for Updates